Information Provided By:
Fly News Breaks for September 13, 2017
Sep 13, 2017 | 07:20 EDT
SunTrust analyst John Boris says that data on AbbVie's (ABBV) UPAD for rheumatoid arthritis shows that its efficacy "appears competitive" with that of Pfizer's (PFE) Xeljanz/XR. The analyst says that the data increases his confidence in AbbVie's opportunity in RA. He keeps a $95 price target and a Buy rating on the shares.
News For ABBV;PFE From the Last 2 Days
Sep 22, 2017 | 07:35 EDT
Notable call activity was cited Thursday in AMD (AMD), Microsoft (MSFT), Intel (INTC), AbbVie (ABBV), Kinder Morgan (KMI), Golar LNG (GLNG), Hasbro (HAS), and Michaels (MIK).
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.